Sotera Health (NASDAQ:SHC) Issues Quarterly Earnings Results

Sotera Health (NASDAQ:SHC) announced its earnings results on Tuesday. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.02, FiscalAI reports. The company had revenue of $303.44 million for the quarter, compared to the consensus estimate of $300.68 million. Sotera Health had a net margin of 4.82% and a return on equity of 43.69%. The company’s revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.21 EPS. Sotera Health updated its FY 2026 guidance to 0.930-1.01 EPS.

Sotera Health Stock Performance

Shares of NASDAQ:SHC opened at $17.49 on Tuesday. The company has a current ratio of 2.38, a quick ratio of 2.18 and a debt-to-equity ratio of 4.04. The stock has a market capitalization of $4.97 billion, a PE ratio of 92.06 and a beta of 1.82. Sotera Health has a 1 year low of $9.53 and a 1 year high of $19.85. The firm has a fifty day moving average price of $17.99 and a 200 day moving average price of $16.81.

Insider Buying and Selling at Sotera Health

In related news, CEO Michael B. Jr. Petras sold 434,104 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $16.45, for a total value of $7,141,010.80. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Pincus & Co. Warburg sold 9,720,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $16.33, for a total value of $158,727,600.00. Following the completion of the sale, the director owned 34,102,952 shares of the company’s stock, valued at approximately $556,901,206.16. This trade represents a 22.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 17,384,104 shares of company stock worth $284,024,511 over the last three months. Corporate insiders own 55.12% of the company’s stock.

Institutional Trading of Sotera Health

Several large investors have recently modified their holdings of SHC. Empowered Funds LLC grew its stake in Sotera Health by 11.1% in the 1st quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after buying an additional 2,845 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Sotera Health by 14.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock valued at $3,999,000 after purchasing an additional 43,471 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Sotera Health by 125.5% in the first quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock valued at $293,000 after purchasing an additional 14,018 shares during the last quarter. Creative Planning increased its stake in shares of Sotera Health by 15.3% in the second quarter. Creative Planning now owns 20,186 shares of the company’s stock worth $224,000 after purchasing an additional 2,673 shares during the period. Finally, Invesco Ltd. lifted its position in shares of Sotera Health by 4.2% during the 2nd quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock worth $3,549,000 after purchasing an additional 12,758 shares during the last quarter. 91.03% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Barclays lifted their target price on Sotera Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. William Blair began coverage on shares of Sotera Health in a research report on Thursday, December 18th. They set an “outperform” rating on the stock. Royal Bank Of Canada started coverage on shares of Sotera Health in a research report on Thursday, January 8th. They issued an “outperform” rating and a $24.00 target price for the company. BMO Capital Markets started coverage on shares of Sotera Health in a research note on Thursday, November 13th. They set an “outperform” rating and a $19.00 target price for the company. Finally, JPMorgan Chase & Co. upped their price target on shares of Sotera Health from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Sotera Health currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.